Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

39.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

623
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Antimicrobial Photodynamic Effect Against Escherichia coli Using MXene-Based Silver-Curcumin 2D Nanocomposite Photosensitizers.

Journal of fluorescence·2026
Same author

Aluminum phthalocyanine chloride loaded poly (lactic-co-glycolic acid) nanoparticles based photodynamic therapy for antibacterial and anticancer applications.

Journal of biotechnology·2025
Same author

A novel anodic nanostructured stainless steel-304L oxide as an emerging electrode material for high energy density asymmetric supercapacitors: experimental and DFT insights.

Nanoscale advances·2025
Same author

Safety and Efficacy of Platelet-Rich Plasma versus Genicular Nerve Radiofrequency Ablation in Knee Osteoarthritis: An Open-Label, Prospective, Randomized, Clinical Trial.

Pain physician·2025
Same author

Synthesis and Antibacterial Studies of Silver Loaded TiO<sub>2</sub> Electrospun Nanofibers Against E. coli by Fluorescence Spectroscopy and Microscopy.

Journal of fluorescence·2025
Same author

Effect of polishing on the morphology of Zircaloy-4 nanostructure: formation of a novel hexagonal nanoscale pattern.

RSC advances·2025
Same journal

BRCAShare: a video-based message can increase sharing of familial genetic test results.

Hereditary cancer in clinical practice·2026
Same journal

Association analysis of germline variants in GEN1 with a susceptibility to prostate cancer in Polish men.

Hereditary cancer in clinical practice·2026
Same journal

Are current Polish guidelines for prophylactic mastectomy sufficient?

Hereditary cancer in clinical practice·2026
Same journal

Renal cell carcinoma risk among individuals heterozygous for fumarate hydratase variants: further insights into genotype-phenotype correlations.

Hereditary cancer in clinical practice·2026
Same journal

Breast cancer specialists' experiences and attitudes towards mainstream genetic testing for patients with breast cancer.

Hereditary cancer in clinical practice·2026
Same journal

Monitoring and treatment patterns of von Hippel-Lindau disease-associated central nervous system hemangioblastomas.

Hereditary cancer in clinical practice·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

PARP inhibitors.

Maheen Anwar1, Hafiz Muhammad Aslam1, Shahzad Anwar2

  • 1Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.

Hereditary Cancer in Clinical Practice
|January 22, 2015
PubMed
Summary
This summary is machine-generated.

Poly (ADP-ribose) polymerases (PARPs) are key proteins in DNA repair. PARP inhibitors show promise as targeted cancer treatments, with ongoing clinical trials for various cancers.

Keywords:
NicotinamidePoly (ADP-ribose) polymerasesRucaparib

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Poly (ADP-ribose) polymerases (PARPs) are crucial proteins involved in DNA repair pathways, particularly base excision repair (BER).
  • The PARP family comprises approximately 17 proteins, with PARP-1, PARP-2, PARP-3, and tankyrases (PARP-5a, -5b) being primary nuclear members.
  • PARP family members regulate diverse cellular processes including DNA repair, transcription, signaling, cell cycle, and mitosis.

Purpose of the Study:

  • To review the mechanism of action of PARP inhibitors.
  • To summarize recent clinical trial data for PARP inhibitors in cancer treatment.
  • To discuss future directions for evaluating PARP inhibitors as anti-cancer drugs.

Main Methods:

  • Literature review of PARP inhibitor mechanisms.
  • Analysis of clinical trial outcomes for PARP inhibitors.
  • Synthesis of current research on PARP family functions.

Main Results:

  • PARP inhibitors target DNA repair pathways, showing efficacy in preclinical and clinical settings.
  • Clinical trials are evaluating PARP inhibitors for breast, uterine, colorectal, and ovarian cancers.
  • The review consolidates insights into PARP inhibitor action and clinical progress.

Conclusions:

  • PARP inhibitors represent a promising targeted therapy class for various cancers.
  • Further evaluation and clinical trials are essential to optimize the use of PARP inhibitors.
  • Understanding PARP functions is critical for developing novel cancer treatments.